KLOW Peptide Dosage — Research Context

TL;DR

There is no established human dose for KLOW peptide. The blend has never been tested in a controlled human study, so there is no clinical dose, no validated titration schedule, and no approved dose range to cite.

What does exist: a canonical research vial composition (80 mg total: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg), and individual component doses used in the preclinical and limited human studies that make up the KLOW peptide research record. Those component doses are not additive into a single 'KLOW dose' — they come from different experiments on different species at different routes.

The page also flags the pharmacokinetic mismatch: the four peptides clear the body at very different rates, which is an inherent structural constraint of any co-formulated vial. This is research context only. No dosing recommendation is made or implied anywhere on this page.

KLOW peptide dosage — the canonical vial

The most widely listed research-vial composition across independent compounders:

80 mg total = GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg

Reconstituted with bacteriostatic water (sterile water with benzyl alcohol as a preservative) for laboratory handling. GHK-Cu at 50 mg is the mass-dominant component — 62.5% of total vial mass — reflecting its role as the matrix-and-follicle arm and its favorable safety profile in cosmetic/topical applications.

No pharmacopeial or FDA-approved KLOW combination product exists. No dose-ranging study for the blend has been published.

Stability note: GHK-Cu contains a chelated copper(II) ion that can participate in redox chemistry (electron-transfer reactions). Co-dissolving it with three other peptides in one vial raises a theoretical compatibility and oxidation question that has not been formally characterized for this mixture.

KLOW dosage — pharmacokinetic mismatch

A pharmacokinetic mismatch (when co-formulated compounds have different absorption and clearance rates, so a single dose cannot maintain all components at matched concentrations) is inherent to the KLOW blend:

• KPV (342.44 Da) and GHK-Cu (402.92 Da) are small tripeptides; small peptides typically clear faster than larger ones.
• BPC-157 (1419.53 Da) is a 15-amino-acid peptide with a short reported elimination half-life under preclinical pharmacokinetic conditions.
• TB-500 (889.02 Da, Ac-LKKTET-Q heptapeptide fragment) has different pharmacokinetics than full-length native thymosin beta-4 (43 amino acids, ~4.9 kDa), from which most of the TB-500 channel's efficacy data derive.

A single co-formulated vial administered at one time cannot hold all four components at matched plasma exposures as they clear at different rates. Which channel is pharmacologically active at any given post-dose time point — and at what effective concentration — is unknown for the blend.

KLOW peptide dosage and frequency — component research context

Component research doses from the published literature (not human prescriptions; not a dosing recommendation; research context only):

GHK-Cu: Topical clinical formulations and nanomolar in-vitro concentrations in collagen synthesis and gene-expression studies ^[4][5]. No systemic human dose range established; topical cosmetic use is the only clinical-grade application.

BPC-157: In rat tissue-repair studies, doses of 10 microgram, 10 nanogram, and 10 picogram per rat administered intraperitoneally once daily were all effective ^[2]. In the first-in-human IV safety pilot, 10 mg was administered on day 1 and 20 mg on day 2 as a 1-hour IV infusion in 250 cc saline — n=2, no adverse events, not an efficacy study ^[6].

TB-500 / thymosin beta-4: In rat wound models, nanomolar topical or IP doses of thymosin beta-4 produced the re-epithelialization results; as little as 10 pg stimulated keratinocyte migration 2-3-fold in vitro ^[1]. Hair-follicle bulge-stem-cell activation work: nanomolar concentrations in vivo/cell culture ^[8]. All of these data are for full-length native thymosin beta-4, not the TB-500 heptapeptide fragment.

KPV: In vitro anti-inflammatory studies: 10 nM in cell culture. Murine colitis studies: 100 micromolar in drinking water. PepT1 substrate Km ~160 micromolar ^[3]. No human dose established.

KLOW dosage — routes studied in the component literature

Routes covered in the single-component literature:

• Subcutaneous injection: the most common research handling route for BPC-157 and TB-500 in community use; subcutaneous data in the formal literature are limited.
• Intraperitoneal injection: the dominant route in rodent BPC-157 and thymosin beta-4 studies ^[1][2].
• Topical: GHK-Cu's primary clinical-grade route (cosmetic wound and skin applications) ^[4]; also used for thymosin beta-4 in Malinda 1999 wound models ^[1].
• Oral / targeted delivery: KPV via PepT1 transporter in gut epithelium; BPC-157 also tested orally in some gastrointestinal models ^[3].
• Intravenous: the 2025 BPC-157 human safety pilot route ^[6]. IV administration was used specifically to study safety — not the standard research handling route.

KLOW peptide blend — no human dose on record

To be explicit: no controlled human study of the four-peptide KLOW blend has established a dose, frequency, duration, or route for human use. The component doses listed above are heterogeneous — different experiments, different species, different routes — and they are not additive into a single blend dose.

This site does not recommend, suggest, imply, or endorse any human dosing approach for the KLOW blend or for any of its four constituents. All content here is editorial commentary on the published research record.